CN1245187C - 一种治疗由脏腑病所致眼病的药物 - Google Patents
一种治疗由脏腑病所致眼病的药物 Download PDFInfo
- Publication number
- CN1245187C CN1245187C CNB031271502A CN03127150A CN1245187C CN 1245187 C CN1245187 C CN 1245187C CN B031271502 A CNB031271502 A CN B031271502A CN 03127150 A CN03127150 A CN 03127150A CN 1245187 C CN1245187 C CN 1245187C
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- medicine
- fructus
- root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 89
- 208000030533 eye disease Diseases 0.000 title claims abstract description 43
- 229940079593 drug Drugs 0.000 title claims abstract description 20
- 208000037911 visceral disease Diseases 0.000 title 1
- 230000000694 effects Effects 0.000 claims abstract description 65
- 238000011282 treatment Methods 0.000 claims abstract description 39
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 34
- 239000000843 powder Substances 0.000 claims abstract description 19
- 239000007788 liquid Substances 0.000 claims abstract description 14
- 241000405414 Rehmannia Species 0.000 claims abstract description 8
- 239000012535 impurity Substances 0.000 claims abstract description 4
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 3
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 3
- 241000628997 Flos Species 0.000 claims description 55
- 210000000582 semen Anatomy 0.000 claims description 27
- 241000756943 Codonopsis Species 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000002775 capsule Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- 239000000284 extract Substances 0.000 claims description 7
- 241000545442 Radix Species 0.000 claims description 6
- 239000004570 mortar (masonry) Substances 0.000 claims description 6
- 238000010025 steaming Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 5
- 239000003643 water by type Substances 0.000 claims description 5
- 241000255791 Bombyx Species 0.000 claims description 4
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 3
- 230000009514 concussion Effects 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 241001071795 Gentiana Species 0.000 claims description 2
- 235000014435 Mentha Nutrition 0.000 claims description 2
- 241001072983 Mentha Species 0.000 claims description 2
- 241000208966 Polygala Species 0.000 claims description 2
- 241001446509 Psoralea Species 0.000 claims description 2
- 241001529739 Prunella <angiosperm> Species 0.000 claims 1
- 239000012153 distilled water Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 23
- 201000010099 disease Diseases 0.000 abstract description 21
- 210000001835 viscera Anatomy 0.000 abstract description 12
- 208000002177 Cataract Diseases 0.000 abstract description 11
- 208000010412 Glaucoma Diseases 0.000 abstract description 8
- 244000189548 Chrysanthemum x morifolium Species 0.000 abstract description 7
- 206010010741 Conjunctivitis Diseases 0.000 abstract description 7
- 230000001154 acute effect Effects 0.000 abstract description 7
- 235000007516 Chrysanthemum Nutrition 0.000 abstract description 6
- 235000013399 edible fruits Nutrition 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 6
- 206010046851 Uveitis Diseases 0.000 abstract description 4
- 201000004484 acute conjunctivitis Diseases 0.000 abstract description 4
- 206010023332 keratitis Diseases 0.000 abstract description 4
- 206010066968 Corneal leukoma Diseases 0.000 abstract description 3
- 206010022941 Iridocyclitis Diseases 0.000 abstract description 3
- 201000004612 anterior uveitis Diseases 0.000 abstract description 3
- 201000005547 chronic conjunctivitis Diseases 0.000 abstract description 3
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 2
- 244000020518 Carthamus tinctorius Species 0.000 abstract 2
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 2
- 229940116229 borneol Drugs 0.000 abstract 2
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 2
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 2
- 241000173529 Aconitum napellus Species 0.000 abstract 1
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 206010011844 Dacryocystitis Diseases 0.000 abstract 1
- 208000010837 Diabetic eye disease Diseases 0.000 abstract 1
- 244000192024 Euphorbia helioscopia Species 0.000 abstract 1
- 235000012043 Euphorbia helioscopia Nutrition 0.000 abstract 1
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 241000736199 Paeonia Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 240000005001 Paeonia suffruticosa Species 0.000 abstract 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 abstract 1
- 240000006079 Schisandra chinensis Species 0.000 abstract 1
- 208000034700 Vitreous opacities Diseases 0.000 abstract 1
- 239000000853 adhesive Substances 0.000 abstract 1
- 230000001070 adhesive effect Effects 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 39
- 239000008280 blood Substances 0.000 description 39
- 230000006870 function Effects 0.000 description 28
- 210000004185 liver Anatomy 0.000 description 28
- 230000004438 eyesight Effects 0.000 description 20
- 210000003734 kidney Anatomy 0.000 description 17
- 230000000844 anti-bacterial effect Effects 0.000 description 15
- 230000036772 blood pressure Effects 0.000 description 15
- 239000009636 Huang Qi Substances 0.000 description 13
- 208000002193 Pain Diseases 0.000 description 13
- 230000007812 deficiency Effects 0.000 description 13
- 230000036407 pain Effects 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 12
- 230000017531 blood circulation Effects 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 230000001077 hypotensive effect Effects 0.000 description 10
- 241000282472 Canis lupus familiaris Species 0.000 description 9
- 206010012735 Diarrhoea Diseases 0.000 description 9
- 241000201295 Euphrasia Species 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 208000001848 dysentery Diseases 0.000 description 9
- 208000001749 optic atrophy Diseases 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 210000004127 vitreous body Anatomy 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 229920002527 Glycogen Polymers 0.000 description 8
- 206010030113 Oedema Diseases 0.000 description 8
- 208000004880 Polyuria Diseases 0.000 description 8
- 230000000202 analgesic effect Effects 0.000 description 8
- 230000035619 diuresis Effects 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 229940096919 glycogen Drugs 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 208000022873 Ocular disease Diseases 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 206010037660 Pyrexia Diseases 0.000 description 7
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 208000002173 dizziness Diseases 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 238000010253 intravenous injection Methods 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 231100000614 poison Toxicity 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 239000000341 volatile oil Substances 0.000 description 6
- 201000000736 Amenorrhea Diseases 0.000 description 5
- 206010001928 Amenorrhoea Diseases 0.000 description 5
- 208000006820 Arthralgia Diseases 0.000 description 5
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 5
- 241000282326 Felis catus Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 5
- 206010034960 Photophobia Diseases 0.000 description 5
- 208000017442 Retinal disease Diseases 0.000 description 5
- 206010038923 Retinopathy Diseases 0.000 description 5
- 208000025865 Ulcer Diseases 0.000 description 5
- 231100000540 amenorrhea Toxicity 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 230000035611 feeding Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 210000001328 optic nerve Anatomy 0.000 description 5
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 5
- 239000002574 poison Substances 0.000 description 5
- 231100000397 ulcer Toxicity 0.000 description 5
- 206010000087 Abdominal pain upper Diseases 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 240000005373 Panax quinquefolius Species 0.000 description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 210000004404 adrenal cortex Anatomy 0.000 description 4
- 230000000954 anitussive effect Effects 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 210000001747 pupil Anatomy 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 229920001864 tannin Polymers 0.000 description 4
- 239000001648 tannin Substances 0.000 description 4
- 235000018553 tannin Nutrition 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 206010009192 Circulatory collapse Diseases 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 208000019255 Menstrual disease Diseases 0.000 description 3
- 241000475481 Nebula Species 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 206010039897 Sedation Diseases 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 208000031971 Yin Deficiency Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 239000003218 coronary vasodilator agent Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 208000001780 epistaxis Diseases 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 230000003419 expectorant effect Effects 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 201000008383 nephritis Diseases 0.000 description 3
- 230000001151 other effect Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000036280 sedation Effects 0.000 description 3
- 206010040560 shock Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- IRLNKOAURQPXIQ-WWWUCTDISA-N Apiopaeonoside Natural products O=C(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO[C@H]3[C@H](O)[C@@](O)(CO)CO3)O2)cc(OC)cc1 IRLNKOAURQPXIQ-WWWUCTDISA-N 0.000 description 2
- 208000004429 Bacillary Dysentery Diseases 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 235000002710 Ilex cornuta Nutrition 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010023644 Lacrimation increased Diseases 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 206010027336 Menstruation delayed Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 206010030043 Ocular hypertension Diseases 0.000 description 2
- 208000003435 Optic Neuritis Diseases 0.000 description 2
- 235000019082 Osmanthus Nutrition 0.000 description 2
- 241000333181 Osmanthus Species 0.000 description 2
- 241000588278 Osmanthus heterophyllus Species 0.000 description 2
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 2
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 2
- IDZZECHGWAZTIB-NYBIBFQCSA-N Paeonolide Chemical compound COC1=CC=C(C(C)=O)C(O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@@H](O)CO3)O)O2)O)=C1 IDZZECHGWAZTIB-NYBIBFQCSA-N 0.000 description 2
- IDZZECHGWAZTIB-WPQJODJHSA-N Paeonolide Natural products O=C(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]3[C@@H](O)[C@H](O)[C@@H](O)CO3)O2)cc(OC)cc1 IDZZECHGWAZTIB-WPQJODJHSA-N 0.000 description 2
- 240000007711 Peperomia pellucida Species 0.000 description 2
- 206010034568 Peripheral coldness Diseases 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 241000295644 Staphylococcaceae Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- HLXRWTJXGMHOFN-XJSNKYLASA-N Verbenalin Chemical compound O([C@@H]1OC=C([C@H]2C(=O)C[C@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HLXRWTJXGMHOFN-XJSNKYLASA-N 0.000 description 2
- 241000607626 Vibrio cholerae Species 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003470 adrenal cortex hormone Substances 0.000 description 2
- IDZZECHGWAZTIB-UHFFFAOYSA-N affinoside Natural products COC1=CC=C(C(C)=O)C(OC2C(C(O)C(O)C(COC3C(C(O)C(O)CO3)O)O2)O)=C1 IDZZECHGWAZTIB-UHFFFAOYSA-N 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000010238 camphora Substances 0.000 description 2
- 229940025250 camphora Drugs 0.000 description 2
- 230000003177 cardiotonic effect Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 208000019902 chronic diarrheal disease Diseases 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000004402 high myopia Effects 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000004410 intraocular pressure Effects 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 230000004317 lacrimation Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- 230000008384 membrane barrier Effects 0.000 description 2
- -1 micro-alkaloid Natural products 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- 206010029410 night sweats Diseases 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 201000005113 shigellosis Diseases 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- BZFBDUQOBQHBSZ-DLCQERRASA-N (3s,8r,9s,10r,13s,14s,17s)-17-[3-(dimethylamino)propyl-methylamino]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol;dihydrochloride Chemical compound Cl.Cl.C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](N(C)CCCN(C)C)[C@@]1(C)CC2 BZFBDUQOBQHBSZ-DLCQERRASA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- KSDSYIXRWHRPMN-UHFFFAOYSA-N 4'-O-beta-D-Galactopyranoside-6''-p-Coumaroylprunin-4',5,7-Trihydroxyflavanone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC(O)=C3C(=O)C2)C=C1 KSDSYIXRWHRPMN-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 241001552669 Adonis annua Species 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 244000000594 Asclepias syriaca Species 0.000 description 1
- 235000002470 Asclepias syriaca Nutrition 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- FYEHYMARPSSOBO-UHFFFAOYSA-N Aurin Chemical compound C1=CC(O)=CC=C1C(C=1C=CC(O)=CC=1)=C1C=CC(=O)C=C1 FYEHYMARPSSOBO-UHFFFAOYSA-N 0.000 description 1
- 208000001992 Autosomal Dominant Optic Atrophy Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- DHHFDKNIEVKVKS-FMOSSLLZSA-N Betanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC(C[C@H]2C([O-])=O)=C1[N+]2=C\C=C\1C=C(C(O)=O)N[C@H](C(O)=O)C/1 DHHFDKNIEVKVKS-FMOSSLLZSA-N 0.000 description 1
- DHHFDKNIEVKVKS-MVUYWVKGSA-N Betanin Natural products O=C(O)[C@@H]1NC(C(=O)O)=C/C(=C\C=[N+]/2\[C@@H](C(=O)[O-])Cc3c\2cc(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)/C1 DHHFDKNIEVKVKS-MVUYWVKGSA-N 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000269417 Bufo Species 0.000 description 1
- 241001060848 Carapidae Species 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010007747 Cataract congenital Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000009604 Chrysanthemum X morifolium Nutrition 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 206010009346 Clonus Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 240000002514 Cymbidium ensifolium Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 241000878003 Dendrolycopodium obscurum Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000909851 Epiphora Species 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 244000153234 Hibiscus abelmoschus Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000244355 Ligusticum Species 0.000 description 1
- DEMKZLAVQYISIA-ONJCETCRSA-N Liquiritin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc([C@@H]2Oc3c(C(=O)C2)ccc(O)c3)cc1 DEMKZLAVQYISIA-ONJCETCRSA-N 0.000 description 1
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 206010030012 Occupational dermatitis Diseases 0.000 description 1
- 208000021957 Ocular injury Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 208000004224 Opium Dependence Diseases 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033971 Paratyphoid fever Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 241000255129 Phlebotominae Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 206010036346 Posterior capsule opacification Diseases 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- 244000179560 Prunella vulgaris Species 0.000 description 1
- 206010065873 Pulmonary fistula Diseases 0.000 description 1
- 206010057071 Rectal tenesmus Diseases 0.000 description 1
- 206010062104 Renal mass Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- HLXRWTJXGMHOFN-UHFFFAOYSA-N Verbenalin Natural products C12C(C)CC(=O)C2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O HLXRWTJXGMHOFN-UHFFFAOYSA-N 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 201000011101 acute retrobulbar neuritis Diseases 0.000 description 1
- 230000002908 adrenolytic effect Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002223 anti-pathogen Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000003260 anti-sepsis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 235000021053 average weight gain Nutrition 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 239000001654 beetroot red Substances 0.000 description 1
- 235000012677 beetroot red Nutrition 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000002185 betanin Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000010234 biliary secretion Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000001709 ictal effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 208000016747 lacrimal apparatus disease Diseases 0.000 description 1
- DEMKZLAVQYISIA-ZRWXNEIDSA-N liquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([C@H]2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-ZRWXNEIDSA-N 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 208000038015 macular disease Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 208000010553 multiple abscesses Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 239000011050 natural pearl Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000002889 oleic acids Chemical class 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 208000027014 optic atrophy 1 Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- RLLPVAHGXHCWKJ-UHFFFAOYSA-N permethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-UHFFFAOYSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 208000018299 prostration Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 206010038464 renal hypertension Diseases 0.000 description 1
- 210000001034 respiratory center Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000004644 retinal vein occlusion Diseases 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 208000022670 retrobulbar neuritis Diseases 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 201000008525 senile cataract Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 1
- 230000002557 soporific effect Effects 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 208000012271 tenesmus Diseases 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008359 toxicosis Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于中医药技术领域,具体是以治疗脏腑病为主,以治疗眼病为辅,标本兼治的中药,主要由冰片、牡丹皮、泽漆、山茱萸、干地黄(包括熟地、生地)、枸杞子、菊花、红花、赤芍、当归、附子、肉桂、党参、黄芪、川芎、五味子、石决明、甘草组成,其工艺是各药分别检查,除去杂质、水洗(除冰片、菊花、红花外)、干燥、烘烤、粉碎、研细、混合、过筛、分装;可制成粉剂和口服液;本发明对由于脏腑疾病引起的眼病,如白内障、玻璃体溷浊、青光眼(开角型)、糖尿病性眼病、急慢性结膜炎、急慢性角膜炎、角膜白斑、泪囊炎、虹膜睫状体炎、葡萄膜炎等有效率可达91%。
Description
技术领域
本发明属于中医药技术领域,具体是以治疗脏腑病为主,以治疗眼病为辅,标本兼治的中药,国际专利分类号:A61K33/06、A61P27/00。
背景技术
中医眼科与西医眼科最大的不同,在于西医眼科以手术为主,药物治疗是辅助手段。而中医眼科则不同,是以治疗为主要手段,却与全身脏腑经络相联系,而且脏腑经络为本,眼部病变为标,急则治标,缓则治本,即标本兼治也可以有所侧重,这样的治疗方法可以得心应手,可获事半功倍之效。在临床中,遇到很多眼病患者,他们的眼病都不是单纯一种眼病,而是两种、三种甚至更多种并混合在一起,因此单一治眼病的疗法都是事倍功半,甚至无功。或者虽然是单一眼病,但因脏腑有重病致患眼病,西医在治疗上同样很麻烦,很不好治。这样就需要用祖国医学中的脏腑学说,以脏腑为主,眼病为辅的治疗方针,标本兼治,凭脉断证,凭证投药,结果疗效就非常。在很多眼病治疗过程中,同样用中医传统方法,而不追求一、二种眼病的治疗,同样取得惊人的效果。
发明内容
本发明的发明目的在于提供一种以治疗脏腑病为主,以治疗眼病为辅,标本兼治的一种治疗由脏腑病所致眼病的药物。
本发明以杞菊地黄汤为基础,其中选用四味干地黄、吴茱萸、泽泻、牡丹皮治肾阴虚;加附子、肉桂以补肾阳,再加枸杞子、菊花以治眼病,疗效颇佳。发明人经多年实践,数千例临床验证,几十次修改,始选定本方。临床实践证明,所有眼病患者除急性症外(如急性结膜炎、眼外伤等),绝大多数都是全身脏腑、经络有这样那样疾患,导致并发眼病。如肝窍于目、肝火盛、肝气郁滞可致眼病;心主一身之血,眼得血而能视,心病血上行不足头部血少,不能供应眼部之充足营养,久之,眼部必患病;肾主一身之水,眼部的一切液体,均由肾主宰,肾功失调,可致眼部疾病,如迎风流泪、眼干涩等;脾运不振,胃纳不佳,使营养不能上荣于目,也很容易致眼病。至于全身疾病,眼同样受损,如糖尿病晚期必致合并眼底病、视网膜病变、眼底出血、玻璃体溷浊、白内障等等,如果不全身治疗糖尿病,不调整脏腑功能,光治眼病,将是事倍功半,甚至全然无功。故标本兼治,以脏腑为主是治疗眼病的基础。本发明已成功地应用于临床。
本发明药物组分是经发明人进行大量摸索总结出的,各组分用量在下述重量份范围都具有较好疗效:
冰片0.5-5份、牡丹皮3-15份、泽漆5-30份、山茱萸3-20份、干地黄(包括熟地、生地)5-30份、枸杞子5-50份、菊花5-40份、红花5-40份、当归5-40份、附子1.5-8份、肉桂3-20份、党参5-50份、黄芪5-50份、川芎5-20份、五味子5-40份、石决明5-30份、甘草5-30份。
本发明优选为:
冰片1份、牡丹皮8份、泽漆6份、山茱萸8份、干地黄(包括熟地、生地)10份、枸杞子15份、菊花10份、红花10份、赤芍10份、当归15份、附子3份、肉桂8份、党参20份、黄芪20份、川芎8份、五味子15份、石决明10份、甘草8份。
本发明药物各组分用量还可以是:
冰片0.5-5份、牡丹皮3-15份、泽漆5-30份、山茱萸3-20份、干地黄(包括熟地、生地)5-30份、枸杞子5-50份、菊花5-40份、红花5-40份、当归5-40份、附子1.5-8份、肉桂3-20份、党参5-50份、黄芪5-50份、川芎5-20份、五味子5-40份、石决明5-30份、石斛10-100份、决明子10-100份、女贞子5-50份、葶苈子10-50份、韭子10-100份、菟丝子10-100份、车前子10-50份、蒺藜子10-50份、补骨脂10-50份。
优选为:
冰片1份、牡丹皮8份、泽漆6份、山茱萸8份、干地黄(包括熟地、生地)10份、枸杞子15份、菊花10份、红花10份、赤芍10份、当归15份、附子3份、肉桂8份、党参20份、黄芪20份、川芎8份、五味子15份、石决明10份、甘草8份、石斛15份、决明子15份、女贞子15份、葶苈子15份、韭子15份、菟丝子15份、车前子15份、蒺藜子15份、补骨脂15份。
本发明药物各组分用量还可以是:
冰片0.5-5份、牡丹皮3-15份、泽漆5-30份、山茱萸3-20份、干地黄(包括熟地、生地)5-30份、枸杞子5-50份、菊花5-40份、红花5-40份、当归5-40份、附子1.5-8份、肉桂3-20份、党参5-50份、黄芪5-50份、川芎5-20份、五味子5-40份、石决明5-30份、磁石25-200份、夏枯草10-200份、茯苓50-200份、合欢10-100份、夜交藤10-100份、天麻10-100份、远志10-100份、僵虫10-100份、石膏10-100份、龙胆草10-100份、柴胡10-100份、姜半夏10-100份、薄荷10-100份、大黄10-50份。
优选为:
冰片1份、牡丹皮8份、泽漆6份、山茱萸8份、干地黄(包括熟地、生地)10份、枸杞子15份、菊花10份、红花10份、赤芍10份、当归15份、附子3份、肉桂8份、党参20份、黄芪20份、川芎8份、五味子15份、石决明10份、甘草8份、磁石25份、夏枯草15份、茯苓50份、合欢15份、夜交藤15份、天麻15份、远志15份、僵虫15份、石膏15份、龙胆草15份、柴胡15份、姜半夏15份、薄荷15份、大黄15份。
本发明的制备方法:
一、粉碎
a)将各药分别检查,除去杂质;除冰片、菊花、红花外,均用水洗1-3遍,以清洁为度;
b)捞出晾晒,至表面干燥即可;
c)将菊花、红花与各药一并放入烤箱内烘烤;
d)烤箱温度在80℃,烘烤40分钟左右,每10分钟左右翻动一次,共需翻动3次,达到内外皆充分干燥为准;将烘干后之各药用药物粉碎机粉碎;
e)将冰片用乳钵研细,与各药混合;
f)将混合后之各药过120目筛;
g)过筛后之药粉分别装入胶囊中;
二、分装
a)过筛后之药粉分别装入胶囊中;
b)每个胶囊装药粉250毫克,即生药760毫克;
c)将胶囊装入容器中密封,以免挥发减效;
d)每个容器装42个胶囊,此为一周服用量。
本发明还可以制成口服液,制备方法中的粉碎之a、b、c、d同前述,
e)将冰片用乳钵研细;
f)除冰片外将各药用水蒸煮;
g)蒸煮后的后的药液浓缩至100毫升流浸膏样液体;
h)用纱布5层过滤2次,至无杂质为度;
i)加入冰片,充分搅动后加蒸馏水200毫升,震荡至完全融合;
j)将药液分装入安瓶中,每瓶5毫升加蒸馏水5毫升,合生药1.52克;
k)将安瓶密封;
l)高温灭菌,110℃,40分钟。
本发明是以杞菊地黄汤为基础之方剂,六味汤为补肾阴之古方,再加枸杞子、菊花以治眼病。枸杞子有滋肾、润肺、补肝明目之功效,治疗目眩、目昏多泪。菊花有疏风清热,疏肝明目解毒之功,临床以之治疗目赤、泪出病后生翳膜、畏光、羞明等。枸杞子、菊花合用相得益彰为治疗眼病的良方。牡丹皮清热凉血、和血消瘀,对多种细菌有抗菌作用、抑菌作用,除此之外,对中枢神经有镇静催眠、镇痛作用。泽漆有行水消痰、解毒明目作用。干地黄含有多种维生素A类物质,有降低血糖作用,并有保护肝脏,防止肝糖元减少的作用。有滋阴养血可治消渴,并有抑菌作用。山茱萸有补肝肾涩精固脱,抗菌抑菌。肾虚则耳聋,肝开窍于目、肝虚则邪热客之而目赤,二脏得补则诸证皆可除也。附子有强心、升压、消炎,并使肾上腺皮质分泌旺盛,促进肝糖之增加,可回阳补火是、散寒除湿。肉桂补元气,暖脾胃,通血脉,有镇痛、解热降温的作用。治命门火衰、肢冷膝微、亡阳虚脱等证。与附子合用,即滋肾阴又补肾阳,阴阳双补。此六味药配伍得当可治多种内脏疾患及因内脏病合并之眼病。本方加入赤勺、红花除凉血疗瘀、活血止血外对心脏循环系统有降压及抑制心脏等作用。本方加入当归能增加肝组织的含氧量,因而能提高全身代谢,对心脏有抑制作用,对多种细菌有抗菌作用。还有对中枢神经有抑制作用,并有利尿作用、镇痛作用、消炎作用,更主要的是其补血和血作用,与红花、赤芍、川芎、党参、黄芪、干地黄等配合,可优势互补,补血补气,滋阴补阳,消炎抗菌,是最佳配伍方式。
另外,当归调经止痛,为治妇女月经不调等疾病之要药,对女性患者之眼病尤为有益。党参、黄芪补中益气,生津利尿。黄芪有强壮作用、降压作用,减缓心律,加强心肌收缩,舒张冠状血管,对治疗循环衰竭,急性肾炎有效。川芎血中气药,对中枢神经系统有镇静作用、降压作用、抗菌作用,并为眼科要药。五味子对中枢神经系统各部位均有兴奋及强壮作用,能提高大脑皮层的调节作用,对呼吸系统有镇咳祛痰作用;对不正常血压有调节作用,对循环衰竭者升高血压颇为显著;能促进肝糖元产生,加强肝糖元分解,可提高血糖和血乳酸的水平。还有滋肾生津、敛汗、涩精等功效,尤其有利于久病体虚之眼病患者。石决明有平肝潜阳除热明目之功效,主治青盲内障,即青光眼。石决明乃足厥阴药也,足厥阴开窍于目,目得血而能视,所以能治多种眼疾。甘草有肾上腺皮质激素样作用,抗炎及变态反应的作用。解毒作用,甘草能显著降低各种有害物质、有害药物的毒性,所以有和诸药而解百毒之说,其镇咳作用为中枢性,其强度与可待因相似。甘草与党参、黄芪、五味子合用有强心及升血压作用。本方配伍大黄主要因其有泄下作用,抗菌作用无论对革氏阳性菌及某些革氏阴性菌均有抗菌作用、抗肿瘤作用;因能缩短血液凝固时间而有止血作用。大黄的功用为泻热毒、破积滞、行瘀血,为阴中之阳药。
本方主要是治眼病,前面介绍的是治疗各脏腑、经络疾患包括治疗眼疾。但药物中更多的是治疗眼病的药物和它们之间的相互配合。如治疗眼底出血、目赤肿痛,有红花、赤芍、牡丹皮、大黄以凉血止血、活血化瘀等等;治疗青光眼、高眼压症以石决明为主配伍大黄效果更佳;川芎为眼科要药,泽膝有明目之功,干地黄能保护肝脏,防止肝糖元减少作用;当归能使肝细胞含氧量增多;山茱萸能补肝肾;五味子能抗脂肪肝,有促进肝细胞新生作用,肝开窍与目,这些药物的配合共治眼病。还有党参能促进肌体新陈代谢作用;枸杞子能激发视神经、视细胞储备功能,菊花能增进视觉细胞功能,可扩大视野,故均可提高和增加眼病患者的视力。冰片有促进其它药物穿透角膜屏障作用,是治疗眼底视网膜、视神经必不可少的药物,故以之为主药。
下面介绍各药药理:
1、冰片
为龙脑科植物龙脑香树脂的加工品,或为樟脑、松节油等化学方法合成的加工制成品。以片大而薄、色洁白、气清香纯正者为佳。药理:止痛及防腐作用,可用于神经痛及消炎;本品辛香走窜,能载药上行;在黏膜、皮下组织均可吸收,在体内与葡萄糖醛酸结合后排出体外。实践证明:冰片可以使角膜上皮细胞的磷脂双分子层运动更加有序,同时还有促进其它药物穿透角膜屏障作用。
2、红花
一年生草本,以花入药。异名:红兰花、刺红花、红花草、红花荣,具特异香气,,味微苦,以花片长、色鲜红、质柔软者为佳。药理:对循环系统有降压及抑制心脏等作用。实验证明:红花除活血化瘀外,并能激发视细胞、视神经储备功能,可增加视力。
3、菊花
异名:节华、金精、甘菊、真菊、家菊、甜菊、药菊、金蕊。为菊科植物菊的头状花序,多年生草本。有白菊、贡菊、滁菊、杭菊。性清香、味淡、微苦。药理:①抗病原体作用:在体外对金色葡萄状球菌及溶血性链球菌,人型结核杆菌有某些抑制作用;②增强毛细血管抵抗力,能抑制毛细血管的通透性而有抗炎作用;③能增进视觉细胞功能。功用主治:疏风、清热、疏肝明目、解毒,治头痛、眩晕、目赤、泪出、去翳膜,治肝肾不足、眼目昏暗、畏光羞明等等。
4、牡丹皮
异名:牡丹根皮、丹皮、丹根。根含牡丹酚、牡丹酚甙、牡丹酚原甙、芍药甙,尚含挥发油0.15-0.4%及植物甾醇等。药理:①对中枢具有镇静、催眠、镇痛作用;②静脉注射丹皮水煎剂,对麻醉犬、猫和大鼠皆有降压作用,实验性高血压(原发型和肾型)犬或大鼠口服,都能出现一定降压作用;③抗菌作用:试管内对白色葡萄球菌、枯草杆菌、大肠杆菌、伤寒杆菌等有较强抗菌作用,对痢疾杆菌、溶血性链球菌、肺炎球菌、霍乱弧菌、金色葡萄球菌等也有抑制作用;④其它作用:对大鼠后肢足踱浮肿有抑制作用,并能降低血管通透性。功用主治:清热、凉血、和血、消瘀、治热入血分、发斑、惊痛、吐衄、便血、骨蒸劳热、闭经、症瘕、痈疡、扑损。
5、泽漆
异名:泽泻、五朵云、乳草。含泽漆皂甙、葡萄糖、果糖、麦芽糖等。药理:有轻度降温作用,对离体兔耳有血管扩张作用。功用主治:行水消疾、杀虫解毒,治水气肿满,痰饮喘咳、疟疾、菌痢、瘰疬、癣疮、结核性瘰管、骨髓炎、食道癌、明目。
6、川芎
异名:芎穷、香果、京芎、抚芎、台芎、西芎。药理:①对中枢神经系统的作用:对动物中枢神经系统有镇静作用;降压作用:水浸剂能降低动物的血压,对麻醉动物(犬、猫和兔)静脉注射降压作用较明显,肌肉注射亦可引起降压;③对平滑肌的作用:川芎浸膏的10%水溶液,微量能刺激受孕子宫,使其活力增高,收缩增强;④抗菌作用:对大肠、痢疾、变形、绿脓、伤寒、副伤寒及霍乱弧菌有抑制作用;功用主治:行气开郁、祛风燥湿、活血止痛,治风冷头痛、眩晕、肋痛、寒痹筋挛、经闭、难产,为眼科要药。
7、山茱萸
异名:蜀枣、山萸肉、枣皮。果皮含山茱萸甙、皂甙、鞣质、熊果酸、没石子酸及维生素A等,种子的脂肪油中有油酸及亚油酸等。药理:①抗菌作用:果实煎剂在体外能抑制金色葡萄球菌的生长,对伤寒、痢疾细菌有抑制作用;②其它作用:流浸膏对麻醉犬有利尿作用,并能使血压降低,体外试验能杀死腹水癌细胞。功用主治:补肝肾涩精气,固虚脱,治腰膝酸痛、眩晕、耳鸣、阳痿、遗精、小便频数、肝虚寒热、虚汗不止、心摇脉散。
8、党参
异名:上党人参、黄参、狮头参、中灵草。党参根含皂甙、微量生物碱、蔗糖、葡萄糖、菊糖、淀粉、粘液及树脂等;药理:①对细胞的影响:水浸液口服或皮下注射,可使正常兔的红细胞及血红蛋白略有增加;②对血糖的影响:对兔皮下注射党参浸膏,可使血糖升高,灌胃给药则无此作用;③降压作用:醇或水浸夜静脉或腹腔注射,能降低麻醉犬的血压,并有某些抗肾上腺素作用;④能促进肌体新陈代谢作用。功用主治:补中、益气、生津,治脾胃虚弱、气血两亏、体倦无力,食少、口渴、久泻、脱肛。
9、黄耆
异名:黄芪、箭芪、戴湛、独湛、蜀脂。含蔗糖、葡萄糖酸粘液质,数种氨基酸、苦味素、胆碱、甜菜碱、叶酸;药理:①利尿作用:对大鼠皮下注射或麻醉犬静脉注射均有利尿作用,并持续时间长,连续7天给药亦不产生耐受性,健康人口服煎剂亦有利尿及钠排除量增加;②对实验性肾炎的作用:大鼠每天服黄耆粉4-5克,3天后尿蛋白定量显著低于对照组,病理切片亦证明肾脏病变减轻,并能加快其恢复到原来水平;③强壮作用:小鼠每日灌服煎剂3周,可明显延长游泳时间,增加体重;④对心血管的作用:可降低动脉压,减缓心率,加强心肌收缩力量以及舒张冠状血管,对循环衰竭及急性肾炎治疗有效。功用主治:生用:益卫固表、利水、消肿、托毒、生肌,治自汗、盗汗、血痹、浮肿,痈疽不溃或溃久不敛;灸用:补中益气,治内伤劳倦、脾虚泻泄、脱肛、气虚血脱、崩带及一切气衰血虚之证,实验证明能促进视细胞繁殖和再生能力。
10、枸杞子
异名:杞子、枸继、仙人杖、元精、枸忌、苦杞。成分含胡萝卜素、硫胶素、核黄素、菸酸、抗坏血酸、亚油酸、β-谷甾醇;药理:①抗脂肪肝作用:有轻度抑制脂肪在肝细胞内沉积,促进肝细胞新生的作用;②拟胆碱样作用:枸杞的水提取物静脉注射,可引起兔血压下降,呼吸兴奋;③实验证明能激发视细胞、视神经的储备功能,故可增加视力。功用主治:滋肾、润肺、明目,治肝肾阴亏、腰膝酸软、头晕目眩、目昏多泪、虚劳咳嗽、消渴、遗精。
11、赤芍药
异名:本芍药、赤芍、红芍药。成分含芍药甙,含挥发油、脂肪油、树脂、鞣质、糖、淀粉、粘液质、蛋白质等;药理:①可以解除腹部挛急作用;②对循环系统,芍药甙可以引起豚鼠血压下降;③镇痛、镇静、抗惊厥作用;④芍药甙有弱的抗炎作用;⑤白芍煎剂在试管内对菌痢杆菌有较强的抑菌作用,对人工发热之小鼠有解热作用。功用主治:行瘀、止痛、凉血、消肿,治淤滞经闭、疝瘕积聚、腹痛、胁痛、衄血、血痢、肠风下血、目赤、肿瘤。
12、大黄
异名:黄良、火参、肤如、将军、锦纹大黄、川军;具有泄下作用,又含鞣酸及其相关物质,有止泄作用;药理:①泻下作用,仅作用于大肠,对小肠无作用因其含有相当数量的鞣质,故在产生下泻之后亦导致便秘;②对革兰氏阳性细菌及某些兰氏阴性细菌在试管中均有抗菌作用;③对小鼠的肉瘤、黑色素瘤、乳腺瘤均有抑制作用,这是对瘤细胞的直接破坏所致;④其它作用:可使兔耳血管收缩,血压轻度上升,还有某些强肾上腺素、乙酰胆碱削弱组织胺的作用,可缩短血液凝固时间,而有止血作用,有促进胰、胆汁的分泌有轻度的促进作用。功用主治:泻热毒、破积滞、行瘀血,治实热便秘、谵语发狂、食积痞满、痢疾初起、里急后重、瘀停经闭、瘕症积聚、时行疫热、吐血、阳黄、水肿、淋浊、溲赤、痈疡肿毒、汤火伤、暴眼赤痛等。大黄阴中之阳药,泻满,推陈致新,去陈垢而安五脏。
13、当归
异名:于归;成分含挥发油,挥发油成分复杂,单是低沸点部分就有10多种,其中有多种烃类,包括3种萜烯,另含有多量蔗糖(40%)、维生素B12、维生素A。根中含棕榈酸、硬脂肪、肉豆蔻及不饱和油酸、亚油酸。药理:①对子宫作用:当归生药中含有两种成分,一种为抑制成分,另一种为兴奋成分。当归对离体子宫(猫、家兔、犬)主要表现为抑制,而对整体动物(猫、家兔、犬)则表现为兴奋作用;②对物质代谢及内分泌的影响,给小鼠吃5%当归的膳食后,能增加肝组织的含氧量,这是提高全身代谢的结果;③对循环系统的影响,心脏:煎剂或流浸膏对离体蟾蜍心脏有抑制作用,静脉注射当归的有效剂量对人工心房纤颤有治疗作用;血压:对麻醉动物有降压作用;当归粉对大鼠动脉粥样硬化之斑块病理过程有某些保护作用;④煎剂在试管中对多种细菌如痢疾杆菌、溶血性链球菌有抗菌作用;⑤对中枢神经系统有抑制作用、镇痛作用、消炎作用。功用主治:补血和血、调经止痛、润燥滑肠,治月经不调、经闭腹痛、症瘕结聚、、崩漏;肠燥难便、赤痢后重;血虚头痛、眩晕、痿痹;痈疽疮疡、跌打损伤。
14、附子
成分含有6种生物碱;药理:①其治疗量对人可使心率减慢,脉搏柔软而弱,血压微降;中毒时极易产生心室纤维颤动;熟附片强心作用较强,煎煮愈久强心愈显著;②能使血压下降,能引起下肢血管显著扩张,尚能扩张冠状血管;有谓急救回阳汤(附子、樟脑、人参、麝香)有升压作用;③对鼠体肾上腺皮质分泌旺盛。磷酸酶活性增强,即增强了糖、蛋白、脂肪的代谢,并促进赶趟元的增加;④对中枢神经有镇痛作用;⑤可抑制呼吸中枢,使呼吸变慢。功用主治:回阳补火、散寒除湿;治阴盛格阳、大汗亡阳、吐利厥逆、心腹冷痛、脾泄冷痢、脚气水肿、小儿慢惊、风寒湿痹、拘挛膝痛、不能行走。
15、石决明
异名:真珠母、鳆鱼甲、千里光、鲍鱼皮、金蛉蜊皮;成分含碳酸钙90%以上,有机质约3.67%,尚含有少量镁、铁、硅酸盐、硫酸盐、磷酸盐等;功用主治:平肝潜阳、除热明目;治风阳上拢、头痛、眩晕、惊搐、骨蒸劳热、青盲内障。选方:①:《圣济总录》石决明散:治眼昏花及头目不利;②治目生白翳:以石决明为主药,配元明粉、菊花、大黄、蝉蜕、白蒺藜,水煎服《山东中草药手册》;③治青盲雀目《眼科龙术论》;④治怕日羞明:千里光汤《眼科龙术论》;I《本草经疏》石决明乃足厥阴药也。足厥阴开窍于目,目得血而能视,所以能主诸目疾也;II《医学衷中参西录》亦称:“石决明为凉肝镇肝之要药。肝开窍于目,是以其性善明目。”
16、五味子
异名:五梅子、玄及;果实含挥发油3%,干果中含柠檬酸、苹果酸及少量酒石酸、单糖类、树脂等,此外还含有叶绿素、维生素C、E等;药理:①对健康人的中枢神经系统各部位均有兴奋及强壮作用,能改善人的智力活动,提高工作效率。其兴奋过程弱于咖啡因,也能加强抑制过程,增大神经过程的灵活性,促进两种神经的相互平衡,提高大脑皮层的调节作用;②对呼吸有兴奋作用、镇咳祛痰作用;③对动物心脏有某些强心作用,对不正常血压有调节作用衰竭者,升高血压颇为显著;④有加强分娩活动的作用;⑤能影响代谢,促进肝糖元产生,加强肝糖元分解,可提高血糖及血乳酸的水平。更有增强肾上腺皮质功能的作用;⑥可提高眼疾患者的视力,扩大视野。能增强肌体对非特异性刺激的防御能力,能促进受损之视网膜恢复功能。功用主治:敛肺、滋肾、生津收汗、涩精;治肺虚喘咳、口干作渴、自汗、盗汗、劳伤赢瘦、梦遗滑精、久泻久痢、增强视力。
17、干地黄
异名:地髓、原生地、干生地;地黄根茎主要含β-保甾醇与甘露醇、地黄索、生物碱、脂肪酸、葡萄糖、维生素A类物质;药理:①八味地黄汤对药物引起的大鼠高血糖有降低作用;②地黄浸膏静脉注射家兔和狗可使血压上升,并有利尿作用;③实验证明:有保护肝脏防止肝糖元减少的作用;④对某些致病性真菌有一定抑制作用。功用主治:滋阴、养血。治阴虚发热、消渴、叶血、衄血、月经不调、胎动不安、阴伤便秘。
18、甘草
甘草的根和根茎含甘草甜素、甘草甙(即甘草素4-β-葡萄糖甙),根尚有雌激素类物资等;药理:①含肾上腺皮质素样作用;②抗炎强度弱于或接近考地松的效果,甘草次酸及其衍化物可制成抗炎抗过敏制剂,用于风湿、气喘、过敏性及职业性皮炎;③对消化系统的作用:对实验性溃疡有明显的抑制作用;对溃疡病的大鼠能降低胃酸效力阿托品的1/2000,与芍药甙合用有协同作用;对离体肠管先兴奋后抑制并能解除乙酰胆碱、组织胺所致之肠痉挛;④解毒作用;⑤对实验性动物动脉粥样硬化能降低血清胆甾醇,并防止其发展;⑥用总胆管瘘管法,可明显增加家兔胆汁分泌;⑦镇咳作用;⑧镇痛抗惊厥作用;⑨可增加茶碱的利尿作用,提取物有女性雌激素作用;⑩实验证明对骨肿瘤有抑制作用。功用主治:和中缓急、润肺、解毒、调和诸药。灸用:治脾胃虚弱、食少、腹痛便溏、劳倦发热、肺瘘咳嗽、心悸、惊痫;生用:治咽喉肿痛、痈疽疮疡、解药毒及食物中毒。
19、肉桂
异名:牡桂、紫桂、桂皮;成分含挥发油1-2%,尚含粘液、鞣质;药理:①对小鼠有明显的镇静作用、镇痛作用,以及解热降温作用;②降压作用附子肉桂复方对肾上腺皮质性高血压大鼠有降压作用,对肾性高血压则无作用;③桂皮油有强大杀菌作用,对革氏阳性菌的效果比阴性者好。功用主治:补元气、暖脾胃、除积冷、通血脉,治命门火衰、肢冷脉微、亡阳虚脱、腹痛泄泻、寒疝奔豚、腰膝冷痛、经闭症瘕、阴疽、流注及虚阳浮越、上热下寒。
主治与服用方法:
1、主治:球后神经炎、视神经萎缩、黄斑区出血、玻璃体溷浊、白内障、开角型青光眼、慢性角膜炎、急慢性结膜炎、角膜白斑、原发性视网膜色素变性、虹膜炎、脉络膜炎、葡萄膜炎等等。
2、应用:视谵混渺、青盲、糖尿病性眼病、各种原因的眼底出血、高眼压、外眼的急慢性炎症、内外障眼病等等。
用量,服用方法、毒副作用、禁忌及注意事项:
用量:每次2粒(500毫克)-4粒(1000毫克)。一日3次。极量一日16粒(4000毫克)。或遵医嘱。
服用方法:食后用温开水吞服,或用姜水吞服更佳。连续服用4周,停药3天,再继续服用,以保安全无虞。
毒副作用:本品微有小毒,按常规用量可保无虞,亦可长期服用,除非必要不宜用极量,并只宜短期服用此量。
禁忌:孕妇忌服。阴虚阳亢者、有过敏史者慎用。
注意事项:
在治疗期间禁烟、酒。尽量少食刺激性食品,如辣椒、胡椒粉等。
对急、重眼病患者或眼底大量出血,视网膜脱落者应及时到医院诊治,可配合使用本发明,不宜依赖本发明,以免延误病情。
对糖尿病患者,在治疗糖尿病同时与本发明配合使用,可受到事半功倍之效。
口服液用量:每次1-2安瓶(500-1000毫克),一日3次,或遵医嘱。
服用方法:食后温开水服之,或用姜水服之更佳,极量4000毫克。其它与前述相同。
本发明治疗由脏腑病变而引起的眼病,不但治疗眼病,而且还治疗引起眼病的内脏腑疾病,效果显著,
本发明治疗效果分类统计如下表:
| 病症 | 痊愈 | 显效 | 有效 | 无效 | 总数 |
| 白内障 | 15 | 25 | 20 | 0 | 60 |
| 玻璃体溷浊 | 15 | 15 | 7 | 3 | 40 |
| 青光眼(开角型) | 8 | 10 | 11 | 1 | 30 |
| 糖尿病性眼病 | 2 | 12 | 8 | 8 | 30 |
| 视神经萎缩 | 1 | 18 | 7 | 4 | 30 |
| 其它(包括急慢性结膜炎、急慢性角膜炎、角膜白斑、泪囊炎、虹膜睫状体炎、葡萄膜炎等等) | 16 | 8 | 4 | 2 | 30 |
| 总计 | 57 | 88 | 57 | 18 | 220 |
| 总有效率91.8% | 无效8.2% | ||||
统计表说明:在整个病案中分类抽出各型眼病220例,治愈、好转的标准依据:人民卫生出版社出版1987.4,第1版,1995.8第5次印刷之总后勤部卫生部编的《临床疾病诊断依据治愈好转标准》统计。
本发明动物实验结果:
1、将6只小猫分成2组,每组3之,大小、体重、月份都相同,一组每日喂食时加本发明药粉0.1毫克,1月后未见任何毒副作用;且喂食药粉组体重增加,身长增长,较未喂药粉者平均增重50克,身长增长3厘米。
2、用鸡雏做实验,10只鸡雏出生15天左右,将其一只眼用半透明塑料布遮盖,其余喂食如常。1月后,取下遮盖布,发现瞳孔灰暗,视力明显低下,已形成内障眼病。健康眼喂食物时,距离100厘米,可清晰看见,内障眼病仅在眼前平均5厘米处始能看见食物。
之后喂食本发明药粉,每日0.1毫克,并观察其病眼变化,10日后可见灰暗之瞳孔趋于正常颜色,而视力有增进,平均为10厘米。1月后增至50厘米。此前因眼部被遮不能正常吃食物,因而体重、身长均受影响。此期间已趋于正常,两个月后眼部变化与正常无异,视力与健康眼相同。未发现任何毒副作用。
3、有一只小狗刚满月,因争食被咬伤左眼,并患了急性角膜炎,经用中药眼药点眼,内服本发明药粉,每日10毫克,3天后炎症减轻,流泪减少,5日后炎症消退。
4、有一只小猫先天性瞳孔发育异常,夜间瞳孔扩大,与白昼无明显差异。经服用本发明,每日3毫克,连服5个月,瞳孔恢复晚间圆形扩大,生活正常。未发现毒副作用。
具体实施方式
实施例1:
取冰片1克、牡丹皮8克、泽漆6克、山茱萸8克、干地黄(包括熟地、生地)10克、枸杞子15克、菊花10克、红花10克、赤芍10克、当归15克、附子3克、肉桂8克、党参20克、黄芪20克、川芎8克、五味子15克、石决明10克、甘草8克。
将上述组分按以下步骤制备:
一、粉碎
a)将各药分别检查,除去杂质;除冰片、菊花、红花外,均用水洗3遍,以清洁为度;
b)捞出晾晒,至表面干燥即可;
c)将菊花、红花与各药一并放入烤箱内烘烤;
d)烤箱温度在80℃,烘烤40分钟左右,每10分钟左右翻动一次,共需翻动3次,达到内外皆充分干燥为准;
e)将烘干后之各药用药物粉碎机粉碎;
f)将冰片用乳钵研细,与各药混合;
g)将混合后之各药过120目筛;
二、分装
a)过筛后之药粉分别装入胶囊中;
b)每个胶囊装药粉250毫克,即生药760毫克;
c)将胶囊装入容器中密封,以免挥发减效;
d)每个容器装42个胶囊。
本发明还可以制成口服液,制备工艺中的粉碎之a、b、c、d同前述,
e)将冰片用乳钵研细;
f)除冰片外将各药用水蒸煮;
g)蒸煮后的后的药液浓缩至100毫升流浸膏样液体;
h)用纱布5层过滤2次,至无杂质为度;
i)加入冰片,充分搅动后加蒸馏水200毫升,震荡至完全融合;
j)将药液分装入安瓶中,每瓶5毫升加蒸馏水5毫升,合生药1.52克;
k)将安瓶密封;
l)高温灭菌,110℃,40分钟。
实施例2:
本发明药物各组分用量是:
冰片1克、牡丹皮8克、泽漆6克、山茱萸8克、干地黄(包括熟地、生地)10克、枸杞子15克、菊花10克、红花10克、赤芍10克、当归15克、附子3克、肉桂8克、党参20克、黄芪20克、川芎8克、五味子15克、石决明10克、甘草8克、石斛15克、决明子15克、女贞子15克、葶苈子15克、韭子15克、菟丝子15克、车前子15克、蒺藜子15克、补骨脂15克。
实施例2主治:视网膜病变、内障眼病、黄斑区病变、前后葡萄膜炎、视网膜色素变性、视神经萎缩,尤其适用患有多种疾病,阴阳俱虚之眼病患者。
实施例3:
本发明药物各组分用量是:
冰片1克、牡丹皮8克、菊花10克、红花10克、赤芍10克、当归15克、附子3克、肉桂8克、党参20克、黄芪20克、川芎8克、五味子15克、石决明10克、甘草8克、磁石25克、夏枯草15克、茯苓50克、合欢15克、夜交藤15克、天麻15克、远志15克、僵虫15克、石膏15克、龙胆草15克、柴胡15克、姜半夏15克、薄荷15克、大黄15克。
实施例3主治:急慢性青光眼、脑中风及其合并之眼病、虹膜睫状体炎、眼底出血、血瞳神、视疲劳、视网膜静脉阻塞、高眼压症。
实施例2和实施例3制法及工艺同实施例1。
本发明疗效病例:
1、袁笑梅,女,37岁,患双眼青光眼7-8年,未手术,眼压20-27mmHg之间,近视-300°--350°,裸眼视力:左眼0.07/右眼0.08;镜检发现慢性青光眼、继发性白内障、玻璃体溷浊及视神经萎缩,经用本发明内服及点用中药眼药等综合治疗,两周后测视力0.1/0.12,5周后0.12/0.12。10周后视力0.25/0.15。白内障、玻璃体溷浊明显减轻,视神经萎缩临床检查基本恢复正常。青光眼有开角型与闭角型之分。本患者为开角型,虽然无发作性剧痛,但慢性进行损害视神经。几年后合并视神经萎缩几乎是百分之百。
2、郭冲,先天性白内障,19岁来诊,两眼视力是眼前手指指数,在西医眼科除了手术再无其它方法。发明人采用中医传统疗法治疗,其结果疗效显著,半年后10厘米可看报纸,50米可看清汽车车牌。
3、李老太太,老年性白内障,已3年不能视物。她绝不手术,不听劝。1992年冬来诊,经检查为晚期过熟型白内障,就是说晶体一碰就碎就是手术也拿不出来整个晶体。经用本发明治疗半年,晶体的溷浊程度锐减,从什麽也看不见,到能做家务,能看眼前面人的面目。全身状况也大大改善,身体也大大强壮了,以前有心脏病、慢性肾炎、脑供血不全等疾病也基本痊愈了。
4、高度近视晚期都得玻璃体溷浊。王淑,中学教师,20年前玻璃体溷浊,20年后严重,几至失明,经多方治疗无效。经查有白内障、视网膜病变、高度近视等,全身为心肾肝脾皆虚、浮肿等多种脏腑疾病。1988年来诊,以本发明为主,配合中药眼药等全方位治疗,半年后基本视力达到生活自理,白内障已全治,玻璃体溷浊、视网膜病变也大为好转。
5、房某,女,60岁,患糖尿病20余年,近几年眼病增重,经常眼底出血。1999年2月就诊时眼底大出血,双眼已几乎无视力,同时又合并玻璃体溷浊、白内障等多种眼病,还有全身疾病。在以止血为主,其它眼病及脏腑功能为辅的治疗方针。同时建议其用胰岛素,一周后眼底出血停止,视力逐渐恢复,5周后玻璃体溷浊、白内障均有不同程度的好转。由于应用了胰岛素血糖12.0降到8.0(mmol/L)。停止治疗后半年左右又出现两次眼底出血,但均很快治疗,达到满意效果。几年过去了,没有再犯,血糖一直维持在8.0mmol/L左右。
糖尿病眼病虽然难治,但只要治疗得法,以本发明加减,急则以眼病为主,脏腑功能为辅,缓则标本兼治。中医眼科采用传统方法,以中医药配合其它疗法中药眼药,完全可以达到满意效果。
6、苏俊,女,25岁,患视神经炎1年余,因治疗不当转为视神经萎缩。1998年春来诊,当时双眼视力均在0.03以下;同时因用了大量激素周身浮肿,走路气喘。面对这样的病患,采用了先治全身,将其激素所致之副作用排除,采用本发明加减,以补虚益气为主要手段,1个月后浮肿消退,气喘消失。然后用本发明治疗,配合中药眼药。半年后眼底变化,视神经萎缩已恢复正常。8个月后视力达到0.3-0.5,达到生活自理。
Claims (4)
1、一种治疗由脏腑病所致眼病的药物,其特征在于它主要由下列重量份的原料药组成:冰片1份、牡丹皮8份、泽漆6份、山茱萸8份、干地黄10份、枸杞子15份、菊花10份、红花10份、赤芍10份、当归15克、附子3份、肉桂8份、党参20份、黄芪20份、川芎8份、五味子15份、石决明10份、甘草8份。
2、一种治疗由脏腑病所致眼病的药物,其特征在于它主要由下列重量份的原料药组成:冰片1份、牡丹皮8份、泽漆6份、山茱萸8份、干地黄10份、枸杞子15份、菊花10份、红花10份、赤芍10份、当归15份、附子3份、肉桂8份、党参20份、黄芪20份、川芎8份、五味子15份、石决明10份、甘草8份、石斛15份、决明子15份、女贞子15份、葶苈子15份、韭子15份、菟丝子15份、车前子15份、蒺藜子15份、补骨脂15份。
3、一种治疗由脏腑病所致眼病的药物,其特征在于它主要由下列重量份的原料药组成:冰片1份、牡丹皮8份、泽漆6份、山茱萸8份、干地黄10份、枸杞子15份、菊花10份、红花10份、赤芍10份、当归15份、附子3份、肉桂8份、党参20份、黄芪20份、川芎8份、五味子15份、石决明10份、甘草8份、磁石25份、夏枯草15份、茯苓50份、合欢15份、夜交藤15份、天麻15份、远志15份、僵虫15份、石膏15份、龙胆草15份、柴胡15份、姜半夏15份、薄荷15份、大黄15份。
4、制备权利要求1、或2、或3所述的药物的方法,步骤如下:
一、粉碎
a)将各药分别检查,除去杂质;除冰片、菊花、红花外,均用水洗1-3遍,以清洁为度;
b)捞出晾晒,至表面干燥即可;
c)将菊花、红花与各药一并放入烤箱内烘烤;
d)烤箱温度在80℃,烘烤40分钟左右,每10分钟左右翻动一次,共需翻动3次,达到内外皆充分干燥为准;
e)将烘干后之各药用药物粉碎机粉碎;
f)将冰片用乳钵研细,与各药混合;
g)将混合后之各药过120目筛;
二、分装
a)过筛后之药粉分别装入胶囊中;
b)每个胶囊装药粉250毫克,即生药760毫克;
c)将胶囊装入容器中密封,以免挥发减效;
d)每个容器装42个胶囊;
或者:
步骤a、步骤b、步骤c、步骤d与前述一、粉碎中的步骤a、步骤b、步骤c、步骤d相同;
e)将冰片用乳钵研细;
f)除冰片外将各药用水蒸煮;
g)蒸煮后的药液浓缩至100毫升流浸膏样液体;
h)用纱布5层过滤2次,至无杂质为度;
i)加入冰片,充分搅动后加入蒸馏水200毫升,震荡至完全融合;
j)将药液分装入安瓶中,每瓶5毫升加蒸馏水5毫升,合生药1.52克;
k)将安瓶密封;
l)高温灭菌,110℃,40分钟。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031271502A CN1245187C (zh) | 2003-09-15 | 2003-09-15 | 一种治疗由脏腑病所致眼病的药物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031271502A CN1245187C (zh) | 2003-09-15 | 2003-09-15 | 一种治疗由脏腑病所致眼病的药物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1596914A CN1596914A (zh) | 2005-03-23 |
| CN1245187C true CN1245187C (zh) | 2006-03-15 |
Family
ID=34658842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031271502A Expired - Fee Related CN1245187C (zh) | 2003-09-15 | 2003-09-15 | 一种治疗由脏腑病所致眼病的药物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1245187C (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3120788A1 (fr) * | 2021-03-22 | 2022-09-23 | Ophtalmis | Composition nutraceutique pour le traitement et la prevention des troubles oculaires |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100415285C (zh) * | 2005-09-29 | 2008-09-03 | 李广中 | 一种补肝丸 |
| CN101607005B (zh) * | 2008-06-20 | 2012-06-27 | 河北以岭医药研究院有限公司 | 一种中药组合物在制备治疗结膜炎药物中的应用 |
| CN102166205B (zh) * | 2010-02-26 | 2015-09-30 | 张筱梅 | 丹皮酚及其衍生物的医药用途 |
| CN102327333B (zh) * | 2011-10-18 | 2013-02-27 | 周国生 | 一种治疗外感风邪所致眼疾的中药及其制备方法 |
| CN103055112B (zh) * | 2012-11-07 | 2015-03-18 | 山东施尔明眼科医院 | 一种治疗葡萄膜炎的中药复方药物组合物 |
| CN103800640A (zh) * | 2014-01-29 | 2014-05-21 | 王维 | 一种治疗青光眼的中药制剂 |
| CN103816317A (zh) * | 2014-03-04 | 2014-05-28 | 济南伟传信息技术有限公司 | 一种治疗结膜炎的中药组合物 |
| CN103860745B (zh) * | 2014-03-13 | 2016-03-16 | 中山大学中山眼科中心 | 一种含西罗莫司的眼用药物组合物 |
| CN103948721A (zh) * | 2014-05-04 | 2014-07-30 | 夏美华 | 一种治疗白内障的药物组合物 |
| CN103961484A (zh) * | 2014-05-04 | 2014-08-06 | 夏美华 | 一种治疗白内障的天然复方药液 |
| CN104324310B (zh) * | 2014-07-11 | 2017-07-21 | 河南省立眼科医院 | 一种用于治疗免疫抑制后真菌性角膜炎的中药组合物及其制备方法 |
| CN104940687A (zh) * | 2015-06-18 | 2015-09-30 | 王峰 | 治疗结膜炎的中药组合物及其制备方法 |
| CN104922299A (zh) * | 2015-06-24 | 2015-09-23 | 郭佃强 | 一种预防和治疗糖尿病性视网膜病变的中草药保健口服液 |
| CN104922448A (zh) * | 2015-07-21 | 2015-09-23 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种治疗眼底出血的中药组合物及其用途 |
| CN105233024A (zh) * | 2015-10-19 | 2016-01-13 | 菏泽海诺知识产权服务有限公司 | 一种治疗泪囊炎的中药药膏 |
| CN105920360A (zh) * | 2016-04-21 | 2016-09-07 | 毕宏生 | 一种含白芍、枸杞的用于眼病防治的药物组合物 |
| CN105796977A (zh) * | 2016-04-29 | 2016-07-27 | 毕宏生 | 一种治疗葡萄膜炎的药物组合物 |
| CN105770479A (zh) * | 2016-05-06 | 2016-07-20 | 毕宏生 | 一种治疗葡萄膜炎的中药组合物及制备方法 |
| CN107334899A (zh) * | 2016-11-12 | 2017-11-10 | 南阳医学高等专科学校 | 一种治疗老年性初发期白内障的中药组合物及其制备方法 |
| CN107714768A (zh) * | 2017-10-17 | 2018-02-23 | 瞿应忠 | 一种治疗内外障疾病的中药组合物及其制备方法和应用 |
| CN108669538A (zh) * | 2018-04-24 | 2018-10-19 | 向伟 | 一种清肝明目保健品 |
| CN115040497A (zh) * | 2022-02-08 | 2022-09-13 | 西北农林科技大学深圳研究院 | 丹皮酚衍生物在预防和治疗白斑综合征中的应用 |
-
2003
- 2003-09-15 CN CNB031271502A patent/CN1245187C/zh not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3120788A1 (fr) * | 2021-03-22 | 2022-09-23 | Ophtalmis | Composition nutraceutique pour le traitement et la prevention des troubles oculaires |
| WO2022200334A1 (fr) * | 2021-03-22 | 2022-09-29 | Ophtalmis | Composition nutraceutique comprenant de l'inuline pour le traitement et la prevention des troubles oculaires ou le desequilibre de la microbiote intestinal |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1596914A (zh) | 2005-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1245187C (zh) | 一种治疗由脏腑病所致眼病的药物 | |
| CN103505630B (zh) | 一种治疗糖尿病的药物及其制备方法 | |
| CN102078520A (zh) | 一种治疗神经性头痛的中药制剂及其制备方法 | |
| CN105233010A (zh) | 一种补肾壮阳酒及其制备方法 | |
| CN103520572A (zh) | 一种用于治疗特应性皮炎的中药组合物及其制备方法 | |
| CN103520621B (zh) | 一种治疗老年性白内障的中药组合物及其制备方法 | |
| CN102166278B (zh) | 一种治疗小儿类风湿性关节炎的中药组合物及其制备方法 | |
| CN1408397A (zh) | 含褪黑素和益智中药的组合物 | |
| CN104223068B (zh) | 一种补肝益肾明目的沙苑子口服液及其制备方法 | |
| CN1297291C (zh) | 一种戒除毒瘾的药物及其制备方法 | |
| CN102631557B (zh) | 治疗白内障、外障、老花眼和近视中药组合物及制备方法 | |
| CN1857666A (zh) | 一种治疗老年期痴呆的中药制剂 | |
| CN104223297B (zh) | 一种延缓衰老的五味子保健口服液及其制备方法 | |
| CN102178781B (zh) | 一种治疗阴囊湿疹的中药组合物及其制备方法 | |
| CN104274754A (zh) | 一种治疗小儿遗尿的中药组合物及其制备方法 | |
| CN1453019A (zh) | 一种治疗中老年眼部疾病的中药及其制备方法 | |
| CN1451422A (zh) | 一种治疗眼底出血症的中药及其制备方法 | |
| CN102988747B (zh) | 一种三刺降三高的冲剂及其制备方法 | |
| CN102846871A (zh) | 一种治疗肝火上炎型眶上神经痛的中药制剂及其制备方法 | |
| CN103520644B (zh) | 用于治疗痰瘀型高脂血症的中药组合物及其制备方法 | |
| CN1201811C (zh) | 一种治疗近视眼的中药组合物及制法 | |
| CN112494569A (zh) | 一种提高免疫力的中药组合物及其制备方法和用途 | |
| CN104162090B (zh) | 一种药物组合物及其制备方法 | |
| CN104223062B (zh) | 一种降压降糖的地骨皮保健口服液及其制备方法 | |
| CN108452079B (zh) | 延缓衰老抑制肿瘤细胞生长及改善微循环的方法和组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |